BACKGROUND: Changes in metabolism have been suggested to contribute to the aberrant phenotype of vascular wall cells, including fibroblasts, in pulmonary hypertension (PH). Here, we test the hypothesis that metabolic reprogramming to aerobic glycolysis is a critical adaptation of fibroblasts in the hypertensive vessel wall that drives proliferative and proinflammatory activation through a mechanism involving increased activity of the NADH-sensitive transcriptional corepressor C-terminal binding protein 1 (CtBP1).
P ulmonary hypertension (PH) is a devastating syndrome with high mortality, affecting both pediatric and adult patients with a wide variety of disorders. 1 The pulmonary vasculature in these patients exhibits significant cellular and structural changes within the intima, media, and adventitia that include augmented proliferation, resistance to apoptosis, and increased production of inflammatory mediators and extracellular matrix proteins. 2 These cellular changes are recapitulated, at least in part, in various animal models of PH. 3 Notably, some of the earliest pathophysiological changes are observed in the pulmonary artery adventitia and include robust proliferation of fibroblasts and accumulation of macrophages. [4] [5] [6] [7] These phenotypic changes in adventitial fibroblasts are maintained ex vivo over multiple passages in culture and are regulated, in part, through epigenetic mechanisms. 4, 5, [7] [8] [9] Collectively, these observations are consistent with the hypothesis that many of the cellular and molecular features of PH resemble hallmark characteristics of cancer. 10, 11 It is increasingly recognized that increased proliferation and inflammatory activation can occur in the context of changes in cellular metabolism toward aerobic glycolysis (the Warburg effect) and that there is an intimate link between metabolic adaptation and functional cellular phenotype. 12, 13 It is important to note that metabolic changes closely resembling those of cancer cells have been reported in PH in endothelial cells, smooth muscle cells, and most recently fibroblasts and have formed the basis for a metabolic theory of PH. 12, 14 Furthermore, findings using in-vivo noninvasive imaging approaches support the hypothesis that the fludeoxyglucose positron emission tomography signal originated in the adventitia where activated fibroblasts and macrophages are observed. 14 However, the mechanisms that link metabolic reprogramming to inflammatory and proliferative pathways in PH remain largely unknown.
C-terminal binding protein (CtBP) comprises a dimeric family of transcriptional repressors encoded by 2 paralogous genes (CTBP1 and CTBP2) that have major roles in animal cell development and cancer and have been suggested to be sensors of the metabolic state of cells that can modulate many aspects of cell phenotype. 15 Overexpression of CtBP is observed in a number of cancers, including prostate, ovarian, colon, and breast. [16] [17] [18] Studies in cancer and nervous system revealed that CtBPs promote cellular survival primarily through repression of Bcl-2 family members and other proapoptotic molecules (PERP, Bax, Bik, Puma, p21, and Noxa), as well as tumor suppressors (eg, p16INK4a and p15 INK4b). 15, 18, 19 Importantly, there is emerging evidence that CtBPs may also function to modulate the inflammatory response. 20 Furthermore, a recent genome-wide analysis in breast cancer provided a more comprehensive description of CtBP repression targets. 18, 21 CtBP targets were categorized into 3 main categories: genes that regulate cell renewal and pluripotency, genes that control genome stability, and genes that regulate epithelial differentiation and prevent epithelial-to-mesenchymal transition, all processes of potential importance in PH pathogenesis. 18, 21 CtBP is unique among transcription factors in the incorporation of a D-isomer-specific 2-hydroxyacid dehydrogenase domain, which reduces or oxidizes substrates using the coenzyme NADH. 15, 18 CtBP recruitment of coenzyme NAD + or NADH induces dimerization, an event necessary for transcriptional repressor activity, linking enzymatic function and transcriptional activity. Although both forms of this dinucleotide are capable of inducing CtBP dimerization, CtBPs bind NADH with up to 100-fold higher affinity than NAD + , suggesting that these proteins are in fact sensitive to the ratio of NADH to NAD + within the nucleus. 22, 23 Thus, metabolic changes in cells that favor increases in free NADH (eg, hypoxia or aerobic glycolysis) activate CtBPs and lead to transcrip-clinical Perspective What is new?
• In pulmonary hypertension, little is known about the molecular mechanisms that link the metabolic state of cells to gene transcription and functional changes in their phenotype. We show that C-terminal binding protein-1, a transcription factor that is activated by increased free NADH, acts as a molecular linker to drive the proliferative and proinflammatory phenotype of adventitial fibroblasts within the hypertensive vessel wall. • This work supports the novel hypothesis that some forms of pulmonary hypertension lead to the rewiring of cellular metabolic programs that use alterations in the cellular redox state to control the activity of C-terminal binding protein-1, which then coordinates expression of a network of genes implicated in cell proliferation, apoptosis resistance, and inflammation.
What are the clinical implications?
• We also found that treatment of fibroblasts from the pulmonary hypertensive vessel and of hypoxic mice with a pharmacological inhibitor of C-terminal binding protein-1, 4-methylthio-2-oxobutyric acid, leads to a normalization of proliferation, inflammation, and the aberrant metabolic signaling. • Our results suggest that targeting this metabolic sensor may be a more specific approach to treating metabolic abnormalities in pulmonary hypertension than use of more global metabolic inhibitors. • It will be important in future studies to determine whether inhibition of C-terminal binding protein-1 can be combined with other vasodilating drugs to effect reversal of established severe forms of pulmonary hypertension.
tional repressor activity. CtBPs may thus be an example of how cellular metabolic status can influence epigenetic control of cell function and fate.
Here, we sought to test a novel hypothesis that in PH the metabolic/redox sensor CtBP1 drives persistent proproliferative, antiapoptotic and proinflammatory activation of pulmonary adventitial fibroblasts by linking metabolic reprogramming (aerobic glycolysis and subsequently increased NADH) to gene transcription. Our approach was first to use RNA sequencing (RNA-Seq) to determine whether metabolic pathways differ between control (CO-Fibs) and pulmonary hypertensive (PH-Fibs). We then performed a detailed metabolic evaluation of both CO-Fibs and PH-Fibs cultured under normoxic conditions using nuclear magnetic resonance (NMR) and mass spectrometry (MS; steady-state and tracing experiments with 13 C-glucose). We assessed NADH directly using MS and fluorescence lifetime imaging (FLIM) in cultured fibroblasts. CtBP1 expression was also evaluated by quantitative polymerase chain reaction (qPCR) and immunostaining approaches. We assessed the functional role of CtBP1 in controlling cell phenotype using both genetic (siRNA) and a novel pharmacological inhibitor of CtBP1, 4-methylthio-2-oxobutyric acid (MTOB), a substrate of CtBP dehydrogenase that has recently been shown to antagonize CtBP transcriptional regulation. 18, 24 Finally, using a hypoxic mouse model of PH, we treated mice with MTOB to prove the concept that CtBP1 could serve as a therapeutic target to inhibit hypoxia-induced cell proliferation and inflammation.
MethOds
A detailed Methods section is provided in the online-only Data Supplement.
animals Neonatal calves and C57BL/6 mice exposed to chronic hypoxia were used in this study. All animal procedures were performed in accordance with the Guidelines for Animal Experimentation established and approved by the University of Colorado Anschutz Medical Campus and Colorado State University Institutional Review boards.
tissue specimen
Lung tissues from hypertensive and control calves (n= 5-7 for each group) and mice (n= 5 for each group) were used for reverse transcription-PCR and immunohistochemical/ immunofluorescent staining analyses. Human lung tissue specimens from subjects with idiopathic pulmonary arterial hypertension (IPAH; n=7) or donor control subjects (n=8) were obtained during lung transplantation and used for qPCR and immunohistochemical staining analysis. The study protocol for tissue donation was approved by the ethics committee (Ethik Kommission am Fachbereich Humanmedizin der Justus Liebig Universität Giessen) of the University Hospital Giessen (Giessen, Germany) in accordance with national law and with Good Clinical Practice/International Conference on Harmonization guidelines. Written informed consent was obtained from each individual patient or the patient's next of kin (AZ 31/93).
cell culture
Isolation of adventitial fibroblasts from distal pulmonary arteries of hypertensive and control calves was performed as described in Methods in the online-only Data Supplement. Human pulmonary artery fibroblasts were derived from patients with IPAH or from control donors undergoing lobectomy or pneumonectomy. All cells were cultured under normoxic conditions. Experiments were performed on cells at passages 5 to 10.
rna sequencing
RNA from bovine CO-Fibs and PH-Fibs (n=6 for each group) was used to perform RNA-Seq analysis. Total RNA was purified, fragmented, and converted to cDNA. Sequencing libraries were made with the TruSeq RNA Sample Preparation kit (Illumina, San Diego, CA). RNA-Seq was performed on a HiSeq2000 sequencer analyzer. Sequence reads were assembled to the annotated UMD3.1 bovine reference genome. 25 Quality control analysis was performed with the CLC Genomics workbench software (CLC Bio, Aarhus, Denmark). All the samples analyzed passed all the quality control parameters, indicating a very good quality.
Data were normalized by calculating the reads per kilobase per million mapped reads for each gene. Statistical analysis was performed with the total exon reads used as expression values by the empirical analysis of differential gene expression tool of CLC Bio Genomic workbench software. This tool is based on the EdgeR Bioconductor package and uses count data (ie, total exon reads) for the statistical analysis. Genes were filtered on the basis of minimum expression >0.2 reads per kilobase per million mapped reads. False discovery rate (FDR) was used for multiple testing corrections. Finally, differentially expressed genes were selected based on fold change (≥2), P value (P<0.01), and FDR value (q<0.1). Detailed methods are provided in the online-only Data Supplement.
real-time reverse transcription-Pcr
Total RNA from cultured cells was isolated using Qiagen Mini Kit (Qiagen, Valencia, CA). Total RNA from tissues was isolated with Trizol. The sequences for all primers are listed in Table I in the online-only Data Supplement. Results are presented as fold change using the Δ-ΔCt method.
Quantitative Multi-nMr Metabolomics and 13 
c-glucose Fluxes
Fibroblasts were incubated with 10 mmol/L 13 C 1 -glucose (glucose with 13 C at C 1 position, Cambridge Isotope Laboratories, Tewksbury, MA) as the exclusive glucose source (and otherwise under standard growth conditions). After 24 hours, cells were extracted with perchloric acid and used for NMR analysis. High-resolution 1 H-, 31 P-, and 13 C-NMR experiments were performed with a Bruker 400-MHz Avance III spectrometer (Bruker BioSpin, Fremont, CA). In cell extracts, intracellular 13 C-glucose and its 13 C-labeled products from glycolysis and the tricarboxylic acid cycle were calculated from 13 C-NMR spectra. Spectra acquisition and metabolite integration were performed with Bruker TopSpin software. Metabolite identification and multivariate partial least squares-discriminant analysis were performed using the Human Metabolome Database. Data were normalized to cell mass.
Ultrahigh-Performance liquid chromatography-Ms-Based direct nadh Measurements and Metabolomics analyses: steady state and U-13 cglucose tracing experiments CO-Fibs and PH-Fibs (n=3 for each group), cultured in normal media or in media supplemented with 10 mmol/L U-13 Cglucose (Cambridge Isotope Laboratories) for 5 minutes and 1, 8, and 24 hours were extracted (2×10 6 cells/mL buffer) and run through a C18 reversed-phase column (Phenomenex, Torrance, CA) through an ultrahigh-performance liquid chromatography (UHPLC) system (Vanquish, Themo Fisher). Metabolite assignment, peak integration for relative quantification, and isotopologue distributions in tracing experiments were calculated through the software Maven (Princeton), against the KEGG pathway database and an in-house validated standard library (>650 compounds, also including NADH; product No. N8129, Sigma Aldrich, IROATech). To determine linearity (r 2 >0.99) and sensitivity of the approach (limit of detection and limit of quantification), NADH was weighed and progressively diluted (from 0.5-5000 injected pmol range; 4 orders of magnitude) before injection through UHPLC-MS. Integrated peak areas were exported into Excel (Microsoft, Redmond, CA) for statistical analysis (t test, ANOVA through the software GraphPad Prism).
Frozen mouse whole-lung tissues were snap-frozen, powered, and weighed in the presence of liquid nitrogen and dry ice, and cold lysis buffer (10 mg tissue/mL buffer) was added. Samples were extracted at 4°C for 30 minutes and centrifuged, and the supernatants were used for metabolomics analysis as described above. Data were normalized by tissue mass. assessment of nadh/nad + ratio NADH/NAD + ratio was determined with an enzymatic cycling reaction using modified methods by Williamson et al 26 as described in Methods in the online-only Data Supplement.
Fluorescence lifetime imaging
To directly visualize NADH level in cells, FLIM of 2-photonexcited NADH was performed at the University of California-Davis Advanced Light Microscopy Core.
inhibition of ctBP1
CtBP1 was inhibited either genetically by siRNA or pharmaceutically by MTOB. Transfection efficiencies are shown in Figure I in the online-only Data Supplement.
cell Proliferation assay
An equal number of cells were plated onto 24-well plates in full DMEM supplemented with 10% bovine calf serum for bovine cells or with 10% fetal bovine serum for human cells and then treated with 2-deoxy-glucose (2-DG; 10 mmol/L), pyruvate (20 mmol/L), MTOB (2.5 mmol/L), CtBP1 siRNA (50 nmol/L), or scrambled siRNA or were left untreated. Cell numbers were counted in triplicate wells on days 1, 2, and 3. In parallel, cells with each type of treatment were collected for reverse transcription-PCR.
chromatin immunoprecipitation assay
Chromatin immunoprecipitation assay was used to study CtBP1 protein interaction with its target gene. Human fibroblasts were cross-linked with ice-cold 1% formaldehyde for 15 minutes, and the reaction was stopped by adding 0.125 mol/L glycine. Cell lysates were centrifuged, and the pellet was sonicated in lysis buffer to shear DNA. Fragmented DNA was precipitated with CtBP1 antibody (EMD Millipore, Billerica, MA) with the use of immobilized recombinant protein A affinity resins (RepliGen, Waltham, MA). Unbound DNA fragments were washed off, and beads were removed with elution buffer. Precipitated protein/ DNA complexes were reverse cross-linked by adding 350 mmol/L NaCl and incubated for 6 hours at 65°C. DNA was then purified and used for PCR analysis.
statistical analysis
Prism software version 5 (GraphPad, Software, Inc 27 ) was used for t test or ANOVA followed by Bonferroni posttest analysis.
Values were expressed as mean±SEM. For basic comparisons of 2 gaussian-distributed sample sets, we used Student t tests. In comparisons of multiple groups, the respective ANOVA (1 way when comparing 1 characteristic, or 2 way if 2 dependent variables were involved) was performed. P values were subject to multiple testing adjustment with Bonferroni correction. Supervised partial least squares-discriminant analysis (Simca, Umetrics, San Jose, CA) was used to determine the variance of metabolic phenotypes in CO-Fibs and PH-Fibs as determined via NMR and MS analyses and were sufficient to discriminate biological samples. To validate partial least squares-discriminant analysis, random permutations were performed through MetaboAnalyst and Multibase (20 random permutations were selected; significance threshold, 0.05; <100 variables tested). FDR (Benjamini Hochberg) was <0.1 for all significant metabolites. Power analysis was performed to ensure that the number of replicates was sufficient to ensure >80% probability to have an FDR<0.1 for all the significant observations (tested through MetaboAnalyst 3.0). Differences with values of P<0.05 were considered statistically significant.
resUlts

Ph-Fibs are Metabolically reprogrammed to aerobic glycolysis
RNA-Seq analysis elucidated >1000 differentially regulated genes in bovine PH-Fibs compared with CO-Fibs (n=6 for each group; P<0.01; fold change >2). Glycolysis/ gluconeogenesis and pyruvate metabolism were identified as 2 of the most significantly upregulated pathways ( Table 1 and Figure IIA in the online-only Data Supplement). In particular, 9 genes that code for enzymes and transporters involved in glucose-to-lactate catabolism were upregulated in PH-Fibs (Table 2) . Validation by reverse transcription-PCR analysis confirmed increased gene expression of the glycolytic genes GLUT1, HK2, and LDHA in both bovine and human PH-Fibs relative to CO-Fibs ( Figure 1A ). In addition, upregulation of GLUT1, GLUT4, and G6PD genes (as well as HK2 and LDHA, which are submitted as part of another manuscript) was observed in vessels isolated by laser capture microdissection of IPAH patients compared with control subjects ( Figure 1B ). Furthermore, upregulation of GLUT1 protein expression was observed in situ in the adventitia of hypoxic hypertensive calves by immunofluorescence ( Figure 1C ) and in vitro in cultured bovine and human PH-Fibs by Western blot ( Figure 1D ).
NMR-and MS-based metabolomics analyses confirmed transcriptomics results, showing that significantly different metabolic phenotypes exist between CO-Fibs and PH-Fibs (Figures IIB, IIC, IIIA, and IIIB in the online-only Data Supplement), as well as metabolic reprogramming to aerobic glycolysis in PH-Fibs (Figure 2 and Figures II and III in the online-only Data Supplement). Glycolytic changes included increased glucose uptake; generation of sugar phosphates, 13 C-glycolytic signature, and 13 Clactate (from 13 C 1 -glucose steady-state NMR analyses; Figures IIC, IIIC, and IIID in the online-only Data Supplement); and increased D-glucose, glyceraldehyde 3-phosphate, pyruvate, and lactate production (from steadystate MS analyses Figure 2A and 2B) .
Finally, PH-Fibs displayed alterations in redox homeostasis as indicated by increased amounts of reduced (GSH) and oxidized (glutathione disulfide, GSSG) glutathione, evidence of use of the NADPH-generating pentose phosphate pathway, and increased phosphogluconate and ribose phosphate ( Figure 2B and Figure A, Quantitative polymerase chain reaction showed significantly higher expression of glucose transporter 1 (GLUT1), hexokinase 2 (HK2), and lactate dehydrogenase A (LDHA) mRNA levels in both bovine and human PH-Fibs compared with CO-Fibs. B, Upregulation of GLUT1, GLUT4, glucose-6-phosphate dehydrogenase (G6PD), monocyte chemotactic protein-1 (MCP1), and stromal cell-derived factor-1 (SDF1) and downregulation of heme oxygenase-1 (HMOX1) were observed in vessels isolated by laser capture microdissection of IPAH patients compared with controls. C, Immunofluorescent staining showed higher expression of GLUT1 (red) in the adventitia (Adv) of chronic hypoxia-induced pulmonary hypertensive bovine lung section compared with control lungs. AW indicates airway; EC, endothelium; L.P., lung parenchyma; and M, media. Scale bar=100 μm. D, Western blot confirmed higher protein expression of GLUT1 in both bovine and human PH-Fibs. Data are presented as mean±SEM; n=3-9. *P<0.05, **P<0.01 vs CO-Fibs or vessels from human donors. drial and cytoplasmic (NOX4-generated) reactive oxygen species production in both human and bovine PH-Fibs. 28 To validate steady-state observations suggesting increased uptake and oxidation of glucose through glycolysis, CO-Fibs and PH-Fibs were cultured under normoxia in the presence of U-13 C-glucose for 5 minutes and 1, 8, and 24 hours. Tracing experiments via UHPLC-MS confirmed significantly increased (P<0.05, ANOVA) glucose uptake and intracellular and supernatant 13 C 1-3 -lactate generation in PH-Fibs as early as 8 hours from normoxic incubation with heavy glucose ( Figure 2C ).
nadh concentrations are increased in Ph-Fibs
To determine whether aerobic glycolysis in PH-Fibs formed the basis of increased concentrations of NADH (reflecting changes in the cellular redox status), FLIM ( Figure 3A , red) and UHPLC-MS-based measurements ( Figure 3B ) were used to visualize free NADH and to directly measure NADH and NAD + . Free NADH was markedly higher in bovine and human PH-Fibs relative to CO-Fibs ( Figure 3A ). Direct measurements of total NADH and NAD + were performed through a targeted UHPLC-MS method, after determining linearity ( Figure IVA in the online-only Data Supplement) of the NADH detection down to a limit of quantification of 500 fmol injected, over 4 orders of magnitude. The results showed significant increased NADH in both bovine and human PH-Fibs compared with CO-Fibs ( Figure 3B ). The NADH/NAD + ratio was also significantly increased in bovine PH-Fibs. The NADH/NAD + ratio was remarkably higher in each human PH-Fib population, but because of the extremely low NAD + value found in 1 human PH-Fib, the overall variability is high, and P=0.07 ( Figure IVB in the online-only Data Supplement). To further validate these observations, we performed an orthogonal and frequently used measure of the NADH/NAD + ratio based on an enzymatic cycling reaction and represented by lactate/pyruvate ratio 26, 29 ( Figure IVC were treated with 2-DG (10 mmol/L) to block glucose metabolism or with pyruvate (20 mmol/L) to directly decrease NADH by providing a substrate for NADH recycling to NAD + by lactate dehydrogenase. FLIM analysis showed the both 2-DG and pyruvate decreased free NADH in bovine and human PH-Fibs ( Figure 3C ). Enzymatic cycling reaction measurement also demonstrated that 2-DG significantly decreased the NADH/NAD + ratio in bovine and human cells ( Figure IVD in the online-only Data Supplement). These decreases in free NADH resulted in a significant reduction in proliferation of both bovine and human PH-Fibs ( Figure 3D ).
aerobic glycolysis is critical for the Proinflammatory Ph-Fib Phenotype
Recent reports demonstrate that proinflammatory activation of macrophages depends on metabolic reprogram-ming to aerobic glycolysis. 30, 31 Similar to observations in activated macrophages, we have previously reported that PH-Fibs express high amounts of proinflammatory mediators. 5, 7 Confirming our previous report of increased MCP1 and SDF1 gene and protein expression in PH-Fibs 7 we detected increased expression of monocyte chemotactic protein-1 and stromal cell-derived factor-1 in vessels isolated by laser capture microdissection of IPAH patients compared with control subjects ( Figure 1B) . Importantly, inhibition of aerobic glycolysis with 2-DG resulted in significantly attenuated transcription of monocyte chemotactic protein-1 and stromal cell-derived factor-1 ( Figure 3E ). Interestingly, recent reports have suggested that metabolic reprogramming to aerobic glycolysis prevents transcription of anti-inflammatory genes. 30 HOMX1 has been regarded as an important anti-inflammatory gene in PH. 32, 33 qPCR analysis from vessels isolated by ORIGINAL RESEARCH ARTICLE 1113 laser capture microdissection of IPAH patients showed decreased expression of the HMOX1 relative to control subjects ( Figure 1B) . Inhibition of aerobic glycolysis with 2-DG resulted in increased expression of HMOX1 in both bovine and human PH-Fibs ( Figure 3E ).
ctBP1 expression is increased in adventitial Fibroblasts in Ph
Considering that aerobic glycolysis promotes increases in free NADH concentrations that in turn increase CtBP1 activity, we questioned whether CtBP1 expression was simultaneously increased in PH-Fibs. Notably, immunofluorescence and immunohistochemical staining demonstrated that CtBP1 protein expression was increased in situ in the mouse and bovine hypoxic PH models and in pulmonary arteries from humans with IPAH relative to control subjects ( Figure 4A ). Importantly, CtBP1 expression was localized primarily to the pulmonary arterial adventitia of hypoxic hypertensive subjects ( Figure 4A) . Consistent with increased expression of CtBP1 in PH-Fibs observed in RNA-Seq analysis (P=0.033, FDR), expression of CtBP1 was increased in both cultured bovine and human PH-Fibs relative to CO-Fibs ( Figure 4B ).
ctBP1 links aerobic glycolysis With Proliferation in Ph-Fibs
Simultaneous increases in CtBP1 expression and NADH accumulation suggest a functional role for CtBP1 in PH-Fibs. Therefore, we next determined the role of CtBP1 in PH-Fib proliferation using siRNA to knock down CTBP1 expression and MTOB (2.5 mmol/L) to inhibit CtBP1 activity. Both siCTBP1 and MTOB significantly inhibited PH-Fib proliferation ( Figure 5A ). We also determined the effects of these agents on the expression of genes involved in cell proliferation and cell survival that had previously been shown to be direct targets of CtBP1 in cancer cells. 15, 18, 24 siCTBP1 and MTOB treatment resulted in significant upregulation of genes that promote growth arrest (eg, cyclin-dependent kinase inhibitors genes P21 and P15) and apoptosis (eg, NOXA and PERP; Figure 5B and Figure V in the online-only Data Supplement). The antiproliferative effect induced by genetic or pharmacological inhibition of CtBP1 was accompanied by a correction of the main metabolic aberrations of bovine and human PH-Fibs. Silencing of CTBP1 or treatment with MTOB resulted in a significant decrease in relative levels of metabolites involved in proliferative anabolic pathways (eg, energy metabolism, nucleotide biosynthesis, and antioxidant reactions; Figure 5C and 5E) and human PH-Fibs ( Figure 5D and 5F).
ctBP1 suppresses anti-inflammatory HMOX1 expression in Ph-Fibs
Because metabolic reprogramming to aerobic glycolysis has been shown to suppress anti-inflammatory genes in macrophages, 34 we hypothesized that disruption of CtBP1 signaling would increase transcription of anti-inflammatory genes in PH-Fibs. As mentioned above, the important anti-inflammatory gene implicated in the pathogenesis of PH, HMOX1, [35] [36] [37] [38] was decreased in IPAH vessels ( Figure 1B) and in PH-Fibs relative to controls ( Figure 6A ). Consistent with the proposed repressive activity of CtBP1, siRNA knockdown or pharmacological A B Figure 4 . c-terminal binding protein 1 (ctBP1) expression is increased in the adventitia of hypertensive pulmonary arteries (Pas) and in isolated hypertensive adventitial fibroblast cells.
A, Immunohistochemistry (dark brown staining) and immunofluorescent staining (green staining; space bar=100 μm) showed that CtBP1 protein is overexpressed in the adventitia (Adv) of chronic hypoxia-induced pulmonary hypertensive (PH) but not control (CO), mouse, human, and bovine PA. AW indicates airway; and M, media. B, Real-time polymerase chain reaction data showed that high CtBP1 expression is maintained under normoxia conditions in fibroblasts cultured from both hypertensive calves and humans with idiopathic pulmonary arterial hypertension (n=4-15; *P<0.05, ***P<0.001 vs CO-Fibs).
inhibition of CtBP1 by MTOB resulted in significantly increased HMOX1 transcription ( Figure 6A ). These findings suggested that HMOX1 was a direct target of the repressive activity of CtBP1, which, to the best of our knowledge, has not been previously reported. We therefore used chromatin immunoprecipitation assay to determine direct binding of CtBP1 to the HMOX1 promoter in human PH-Fibs. We also examined whether 2-DG, pyruvate, or MTOB would decrease recruitment of CtBP1 to the HMOX1 promoter. HMOX1 promoter binding was significantly higher in PH-Fibs compared with CO-Fibs. Knockdown of CTBP1 by siRNA decreased binding of CtBP1 to the HMOX1 promoter. 2-DG, pyruvate, and MTOB also suppressed binding of CtBP1 to the HMOX1 promoter region ( Figure 6B ).
MtOB inhibits Proliferation and inflammation in Vivo in a Mouse Model of hypoxic Ph
In light of the ability of MTOB to attenuate proliferation, correct metabolism, and reduce inflammation of cultured PH-Fibs, we next sought to determine the therapeutic potential of MTOB in vivo in a mouse model of hypoxic PH (mice were chosen because the extremely high cost of the compound; eg, the cost of similar experiments in rats was calculated to exceed $35 000). Initial time course experiments using different time points of hypoxic exposure (4, 14, and 28 days) performed to determine longitudinal expression of known genes involved in cellular proliferation and inflammatory activation demonstrated that expression of most of these genes peaked at day 4 ( Figure VIA in the online-only Data Supplement), which is consistent with previous studies in hypoxic mice. 38, 39 Hypoxic (4 days) whole mouse lung tissue exhibited increased glycolysis compared with normoxia as evidenced by the accumulation of lactate and increased NADH/NAD + ratios ( Figure 7A and 7B) . Metabolomics analyses by MS indicated a progressive alteration of lung normoxic metabolic phenotype during prolonged exposure to hypoxia, alterations that were corrected by the MTOB treatment ( Figure 7C ). Specifically, MTOB corrected the hypoxia-induced increase in glucose consumption and prevented the accumulation of glycolytic intermediates (glyceraldehyde 3-phosphate) and products (NADH/NAD + ratios [ Figure 7B ] and lactate [ Figure 7A and 7D]). At day 4 of hypoxia, qPCR data demonstrated an 8-fold increase in the expression of the proproliferative gene CDK1 (cyclin-dependent kinase 1), which was inhibited by MTOB treatment (Figure 8A ). Immunostaining for Ki67 nuclear proliferation-associated antigen revealed that at 4 days of hypoxia, the number of proliferating lung cells was significantly increased and that MTOB treatment markedly decreased the number of proliferating cells ( Figure 8B) . These changes were especially prominent in the distal pulmonary vasculature and in lung parenchyma. Furthermore, qPCR analysis of the whole-lung tissue demonstrated that hypoxia promoted monocyte chemotactic protein-1 (Mcp1/Ccl2) mRNA expression and that MTOB treatment attenuated it ( Figure 8C ). Correspondingly, we demonstrated an influx of monocytes/macrophages (expressing the macrophage marker CD68) into pulmonary vascular adventitia of hypoxic hypertensive mice, and this proinflammatory response was markedly attenuated in distal pulmonary vasculature by MTOB treatment ( Figure 8D ). Last, to assess early pulmonary vascular remodeling (at day 4 of hypoxic exposure, before any significant deposition of collagen can be identified), we determined mRNA and protein expression of tenascin-C (TN-C), a matricellular protein with an expression that is sharply upregulated in tissues undergoing remodeling, neovascularization, inflammation, or tumorigenesis. 40 At day 4 of hypoxic exposure, TN-C mRNA expression in lung tissues was upregulated 4-fold compared with normoxic controls, and TN-C protein was prominent in distal pulmonary vasculature ( Figure 8E and 8F) . MTOB treatment attenuated TN-C expression at mRNA and protein levels ( Figure 8E and 8F). We did not observe significant differences in CDK1, TN-C, and monocyte chemotactic protein-1 mRNA levels between untreated and MTOB-(1g/kg) treated normoxic mice (online-only Data Supplement Figure VIB) . Hematoxylin and eosin staining and α-smooth muscle actin staining also showed perivascular inflammation and vascular remodeling, respectively, in hypoxic mice lung A B Figure 6 . c-terminal binding protein 1 (ctBP1) directly regulates HMOX1 gene expression in pulmonary artery adventitial fibroblasts. tissue, and both were attenuated by MTOB treatment (online-only Data Supplement Figure VII) . Taken together, MTOB treatment of hypoxic hypertensive mice successfully attenuated pulmonary vascular cell proliferation, inflammation (as seen by the reduction in Ccl2/Mcp1 expression and decreased recruitment of CD68-expressing macrophages), and vascular remodeling (TN-C, α-smooth muscle actin, and hematoxylin and eosin staining).
discUssiOn
In the present study, we have demonstrated that in the pathogenesis of PH, adventitial fibroblasts undergo metabolic reprogramming with increased aerobic glycolysis relative to oxidative phosphorylation. Our findings expand on our previous observations of anomalous mitochondrial metabolism in PH and highlight the critical function of metabolic adaptations in supporting fibroblast proliferation and inflammatory activation. 28 We have also demonstrated increased expression of CtBP1 in the lungs of hypoxia-induced experimental PH in the cow and mouse model and in patients with IPAH patients and linked that expression to disease pathogenesis. It is important to note that we identified CtBP1, a transcriptional corepressor that is activated by increased free NADH secondary to glycolytic reprogramming, as a molecular link and potential therapeutic target to correct the aberrant metabolic, hyperproliferative, and inflammatory phenotype of bovine and human PH-Fibs in vitro and in hypoxic mice in vivo. Our study thus supports the novel hypothesis that chronic hypoxic PH and seemingly IPAH or familial pulmonary arterial hypertension lead to the rewiring of cellular metabolic programs that use alterations in the cellular redox state (ie, available NADH) to control activity of CtBP1 and thus coordinate expression of a network of genes implicated in cell proliferation, apoptosis resistance, and inflammation ( Figure 8G ).
PH pathology often involves an imbalance of cell proliferation versus cell death; thus, the hypothesis has been put forth that the cellular and molecular features seen in PH resemble hallmark characteristics described Figure 7 . hypoxia (hx)-induced glycolysis reprogramming and increased nadh level in mouse lung tissue, and 4-methylthio-2-oxobutyric acid (MtOB) rescued the metabolic phenotype back to normoxic (nx) controls.
A and B, Hypoxic exposure of mice (4 days) increased lactate production and the NADH/NAD + ratio in whole-lung tissues compared with their normoxic controls. Animals were pretreated with MTOB for a week (3 times a week; intraperitoneal injection with 2 different doses: 0.75 or 1 g/kg) and received 2 more injections after being put into hypoxia chamber. MTOB decreased the lactate level and NADH/NAD + ratio in hypoxia-exposed lungs (determined by enzymatic cycling reaction; n=3-5; *P<0.05, **P<0.01 vs normoxic lungs; #P<0.05, ##P<0.01 vs hypoxic lungs). Mass spectrometry (MS) metabolomic analysis discovered that (C) the overall metabolic profile of mouse lung tissue becomes increasingly altered from its normoxic state as hypoxia exposure continues, yet MTOB was able to recover the metabolic state of lung tissue back to normoxic control levels (n=5 in each group) and that (D) MTOB decreased glucose consumption, glyceraldehyde-3-phosphate production, a substrate for GAPDH to generate NADH, and lactate production (n=5; *P<0.05, **P<0.01 vs mouse whole-lung tissue not treated with MTOB). for cancer. 11, 12, 41 Changes in metabolism have emerged as key contributors to cancer pathophysiology and inflammation and thus have become emerging targets for novel diagnostic and therapeutic approaches that may have relevance to PH. 11, 41, 42 Our study provides strong evidence that in vivo and in vitro aerobic glycolysis is a metabolic adaptation in pulmonary artery adventitial fibroblasts in the setting of chronic hypoxia and in IPAH. Metabolic data here suggest that, akin to Warburg metabolism in cancer cells and inflammatory macrophages, incomplete glucose oxidation provides PH-Fibs with building blocks to support anabolic reactions (amino acid anabolism, fatty acid synthesis, urea cycle, gluconeogenesis) necessary to sustain proliferation and inflammatory activation, counteract oxidative stress, and promote resistance to apoptosis.
Unlike other transcriptional corepressors, CtBP1 is uniquely structured to sense increases in free NADH concentrations that typically occur secondary to glycolytic reprogramming. 22, 23 Studies by our group and others have demonstrated that changes in the cellular reducing environment alter the interaction of CtBP1 with DNA-binding transcriptional repressors. 23, 29, 43, 44 As a foe of multiple tumor suppressors, CtBP1 also provides a link between transcriptional regulation and the metabolic status of the cell. 15 In line with the hypothesis that free NADH concentrations increased CtBP activity, treatment of PH-Fibs with 2-DG or pyruvate to interfere with aerobic glycolysis or promote NADH oxidation to NAD + in PH-Fibs, respectively, was associated with attenuation of activity of CtBP1. Decreased CtBP1 activity translated to reduced PH-Fib proliferation and attenuated inflammatory activation, normalization of aberrant metabolic phenotypes, and increased expression of anti-inflammatory HMOX1. In PH-Fibs (both bovine and human), this increase in CtBP1 activity was maintained in the absence of a hypoxic stimulus, indicating that, akin to what has been described in cancer cells, stable rewiring or reprogramming of metabolism occurs in PH-Fibs and drives activity of transcriptional repressors such as CtBP1. It is striking that knockdown of CTBP1 by siRNA or inhibition of CtBP1 dehydrogenase activity by MTOB treatment attenuated the proliferation of PH-Fibs ( Figure 5A ). Similar to cancer cells, inhibition of CtBP1 increased expression of cyclin-dependent kinase inhibitors (p15 and p21) and proapoptotic genes (NOXA and PERP). 18, 23 Our findings of an important role for CtBP1-mediated change in cell phenotype in PH are consistent with previous findings in PH. It was recently reported that hypoxia, a paramount stimulus for the development of PH, suppresses the expression of inhibitor of differentiation 1, a downstream target of the bone morphogenetic protein receptor type II pathway, in human pulmonary artery smooth muscle cells. 45 Hypoxia-induced changes in the NADH/NAD + ratio and histone deacetylases upregulated transcriptional corepressor CtBP-1 activity and subsequently attenuated bone morphogenetic protein signaling. 45 As a result of the near-universal association between metabolic reprogramming and an activated cell phenotype in both cancer and PH, there has been great interest in identifying factors that might link these changes. CtBPs have emerged as candidates in this regard. It is important to note that we also observed significantly reduced levels of inhibitor of differentiation 1 and 2 in PH-Fibs with high CtBP1 expression ( Table 2 ). These findings are furthermore consistent with the proposed role of CtBPs in tumor genesis and tumor progression as we observed similar CtBP1 targets, including p15, p21, NOXA, and PERP. 15, 18, 24 Inflammation is critically involved in the pathogenesis of PH, although how this is related to or regulated by metabolic reprogramming is unclear. 41 Because of its prominent role in the pathogenesis of PH, we focused attention on the anti-inflammatory gene HMOX1 and demonstrat- ed that inhibition of aerobic glycolysis was associated with robust increases in HMOX1 expression. The results showed that HMOX1 is a direct target of CtBP1, which has not previously been reported. Heme oxygenase (HO) catalyzes the oxidation of heme to carbon monoxide and biliverdin, which is then converted to bilirubin by biliverdin reductase. 46 Carbon monoxide released by HO-1 confers protection against vasoconstriction and vascular remodeling induced by hypoxia in vitro. 47, 48 Studies using an HO-1-null mouse model suggest that HO-1 plays a central role in protecting the right ventricle from hypoxic pulmonary pressure-induced injury. 49 In contrast, transgenic mice with constitutive, lung-specific overexpression of HO-1 do not manifest the early inflammatory changes and are protected against PH on continued exposure to hypoxia, 32 suggesting that increasing HO-1 can serve as a prevention or therapeutic intervention for PH. In all, our findings suggest that it is possible that targeting CtBP1 has the potential to convert proinflammatory activation to an anti-inflammatory phenotype and thus to suppress inflammation and vascular remodeling, as was observed in our MTOB-treated hypoxic mice.
Until recently, CtBP1 had been implicated in responding to the metabolic status of the cell rather than regulating the cellular metabolic pathways. 18, 50 It is interesting to note that a recent study demonstrated that CtBP promotes glutaminolysis in cancer cells by directly decreasing SIRT4 gene expression, a mitochondrial repressor of glutamate dehydrogenase and thus glutaminolysis. Therefore, increased CtBP levels in cancer cells repress SIRT4, which in turn leads to an increase in glutamine supply that promotes ammonia production to neutralize the acidification associated with increased glycolytic fluxes. 51 Because glycolytic rate drops as pH falls, the role of CtBP1 in preventing intracellular acidification sustains glycolysis and, in turn, cancer cell growth. RNA-Seq and metabolomic analysis from our study are consistent with these findings, showing higher level of glutamate dehydrogenase (P=0.02, FDR) together with significantly decreased SIRT4 level ( Table 2) in PH-Fibs with concomitant increases in the expression and activation of CtBP1. Consistently, inhibition of CtBP1 by siRNA or MTOB corrected the metabolic phenotype of PH-Fibs and mouse lung tissue ( Figures 5C-5F , 7C, and 7C). In particular, MTOB treatment prevented the accumulation of glycolytic reprogramming induced by prolonged exposure to hypoxia in mouse lungs ( Figure 7C ). Indeed, although prolonged hypoxia promoted increases in glycolysis in mice lungs, MTOB treatment resulted in normoxic-like levels of glyceraldehyde 3-phosphate, lactate, and NADH/NAD + ratios (Figure 7) . Thus, similar to cancer, the proliferation-promoting function of CtBP1 in PH-Fibs requires its involvement in metabolic control. We have previously reported that the PH-Fibs described in this study fail to exhibit high expression levels of αsmooth muscle actin and Col1 and in fact continue to express markers of mesenchymal progenitors such as RGS5 ( Table 2 ). CtBP1 could thus be an essential regulator to support self-renewal and expansion, particularly in hypoxic environments as might be observed at the medial-adventitial border of inflamed vessels. Of note, metabolic reprogramming toward aerobic glycolysis was observed in PH-Fibs cultured under normoxia, suggesting that whether hypoxia represents a key trigger to promote metabolic reprogramming and CtBP1 activation, hypoxia-independent perpetuation of the metabolic reprogramming-CtBP1 activity axis results in a feed-forward mechanism that can be disrupted by pharmacological or genetic ablation of either component of the axis in vitro and in vivo.
Last, our ex-vivo data demonstrate that targeting CtBP1 at the RNA level via siRNA or at the activity level by MTOB or reducing NADH level by 2-DG or pyruvate can inhibit the proliferative and augment the anti-inflammatory phenotype of PH-Fibs. These results provide evidence that small molecules such as MTOB or NSC9539 (a CDC25 inhibitor that inhibits the CtBP1-adenovirus E1A protein interaction) that demonstrate anticancer properties may be used as tools to treat hypoxia-induced PH. 52, 53 As a first step in examining this hypothesis, we treated mice made hypoxic with MTOB (at present a prohibitively expensive drug). We found that MTOB successfully attenuated vascular remodeling (cell proliferation, glycolytic and overall metabolic reprogramming, macrophage accumulation, and extracellular matrix production) induced by hypoxia. Thus, it is tempting to speculate that in certain forms or stages of PH, including hypoxia (group 3), targeting the transcriptional repressor CtBP1, which links changes in metabolism to an activated cell phenotype, may have beneficial effects.
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